The case against censoring of progression-free survival in cancer clinical trials – A pandemic shutdown as an illustration

BACKGROUND: Missing data may lead to loss of statistical power and introduce bias in clinical trials. The Covid-19 pandemic has had a profound impact on patient health care and on the conduct of cancer clinical trials. Although several endpoints may be affected, progression-free survival (PFS) is of...

Descripción completa

Detalles Bibliográficos
Autores principales: Jamoul, Corinne, Collette, Laurence, Coart, Elisabeth, D’Hollander, Koenraad, Burzykowski, Tomasz, Saad, Everardo D., Buyse, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532825/
https://www.ncbi.nlm.nih.gov/pubmed/36199019
http://dx.doi.org/10.1186/s12874-022-01731-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532825/
https://www.ncbi.nlm.nih.gov/pubmed/36199019
http://dx.doi.org/10.1186/s12874-022-01731-5

Ejemplares similares